182 related articles for article (PubMed ID: 32943831)
1. Clinical Experience in the Administration of Intravitreal Injection Therapy at a Tertiary University Hospital in Jordan During the COVID-19 Lockdown.
Saleh OA; Jammal H; Alqudah N; Alqudah A; Abu-Yaghi N
Clin Ophthalmol; 2020; 14():2473-2480. PubMed ID: 32943831
[TBL] [Abstract][Full Text] [Related]
2. [Impact of the SARS-CoV-2 pandemic on diabetic macular edema and prognostic factors].
Khodriss C; El Harch I; Bennis A; Chraibi F; El Fakir S; Abdellaoui M; Tachfouti N; Benatiya Andaloussi I
J Fr Ophtalmol; 2021 Nov; 44(9):1313-1318. PubMed ID: 34538511
[TBL] [Abstract][Full Text] [Related]
3. Delayed Intravitreal Anti-VEGF Therapy for Patients During the COVID-19 Lockdown: An Ethical Endeavor.
Elfalah M; AlRyalat SA; Toro MD; Rejdak R; Zweifel S; Nazzal R; Abu-Ameerh M; Ababneh O; Gharaibeh A; Sharif Z; Meqbil J; AlShawabkeh M; Alwreikat A; Al Bdour M; Al-Hussaini M; Yousef YA
Clin Ophthalmol; 2021; 15():661-669. PubMed ID: 33628009
[TBL] [Abstract][Full Text] [Related]
4. Effects of COVID-19 on Intravitreal Injection Clinic After Lockdown.
Hsieh T; Gundlach BS; Ashrafzadeh S; Sarraf D; Tsui I
Clin Ophthalmol; 2022; 16():3089-3096. PubMed ID: 36160732
[TBL] [Abstract][Full Text] [Related]
5. INTERNATIONAL IMPACT OF THE COVID-19 PANDEMIC LOCKDOWN ON INTRAVITREAL THERAPY OUTCOMES: Fight Retinal Blindness Registry.
Zarranz-Ventura J; Nguyen V; Creuzot-Garcher C; Verbraak F; O Toole L; Invernizzi A; Viola F; Squirrel D; Barthelmes D; Gillies MC;
Retina; 2022 Apr; 42(4):616-627. PubMed ID: 34907129
[TBL] [Abstract][Full Text] [Related]
6. [Impact of the French 2020 COVID-19 lockdown on the treatment and follow-up of patients with exudative age-related macular degeneration].
Auger A; Khanna RK; Bonicel P; Pisella PJ; Le Lez ML
J Fr Ophtalmol; 2023 Jun; 46(6):596-604. PubMed ID: 37248127
[TBL] [Abstract][Full Text] [Related]
7. Outcome of Patients Treated by Intravitreal Injections During the COVID-19 Lockdown: An Institutional Experience.
Sukkarieh G; Bonnin S; Azar G; Lafolie J; Alonso AS; Erol O; Pineau J; Villain H; Guillaume J; Auge E; Mingou A; Lejoyeux R; Vasseur V; Mauget-Faÿsse M
Curr Eye Res; 2023 Jul; 48(7):683-689. PubMed ID: 37024478
[TBL] [Abstract][Full Text] [Related]
8. The importance of monitoring wet age-related macular degeneration patients during Coronavirus disease 19 pandemic: A retrospective study of assessment of functional and structural outcomes.
Tsiropoulos GN; Vallee R; Gallo Castro D; Ambresin A
J Fr Ophtalmol; 2022 Oct; 45(8):852-859. PubMed ID: 35908993
[TBL] [Abstract][Full Text] [Related]
9. Impact of COVID-19-related lockdown on retinal disorders treated with intravitreal injections.
Brar M; Grewal SPS; Grewal DS; Sharma M; Dogra MR
Oman J Ophthalmol; 2022; 15(2):168-174. PubMed ID: 35937740
[TBL] [Abstract][Full Text] [Related]
10. The Influence of COVID-19 Lockdown in Jordan on Patients with Diabetic Retinopathy: A Case-Control Study.
Al-Dwairi R; Rwashdeh H; Otoom M
Ther Clin Risk Manag; 2021; 17():1011-1022. PubMed ID: 34584415
[TBL] [Abstract][Full Text] [Related]
11. TREATMENT DEFERRAL DURING COVID-19 LOCKDOWN: Functional and Anatomical Impact on Patients With Neovascular Age-Related Macular Degeneration.
Montesel A; Gigon A; Giacuzzo C; Mantel I; Eandi CM
Retina; 2022 Apr; 42(4):634-642. PubMed ID: 34907122
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
13. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
14. Short-term efficacy of intravitreal bevacizumab for the treatment of macular edema due to diabetic retinopathy and retinal vein occlusion.
Astam N; Batioğlu F; Ozmert E
Int Ophthalmol; 2009 Oct; 29(5):343-8. PubMed ID: 18553061
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Delay in Care among Patients Requiring Intravitreal Injections.
Song W; Singh RP; Rachitskaya AV
Ophthalmol Retina; 2021 Oct; 5(10):975-980. PubMed ID: 33395587
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion.
Ip MS; Gottlieb JL; Kahana A; Scott IU; Altaweel MM; Blodi BA; Gangnon RE; Puliafito CA
Arch Ophthalmol; 2004 Aug; 122(8):1131-6. PubMed ID: 15302652
[TBL] [Abstract][Full Text] [Related]
17. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion.
Cekiç O; Chang S; Tseng JJ; Barile GR; Weissman H; Del Priore LV; Schiff WM; Weiss M; Klancnik JM
Retina; 2005; 25(7):846-50. PubMed ID: 16205562
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal versus retrobulbar injections of triamcinolone for macular edema associated with branch retinal vein occlusion.
Hayashi K; Hayashi H
Am J Ophthalmol; 2005 Jun; 139(6):972-82. PubMed ID: 15953425
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Treatment Discontinuation During the COVID-19 Pandemic on Visual Acuity in Exudative Neovascular Age-Related Macular Degeneration: 1-Year Results.
Stattin M; Ahmed D; Graf A; Haas AM; Kickinger S; Jacob M; Krepler K; Ansari-Shahrezaei S
Ophthalmol Ther; 2021 Dec; 10(4):935-945. PubMed ID: 34374028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
